Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference

Biodel to Present New Preclinical Glucagon Data During Corporate Overview at
JMP Securities Healthcare Conference

DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD)
announced today that management will present new preclinical pharmacokinetic
and pharmacodynamic data on its glucagon formulation intended for use in a
novel auto-reconstitution device. Biodel's glucagon injection system is
designed to improve on existing treatments for severe hypoglycemia. These data
will be presented during a corporate overview of the Company on Tuesday, July
9, 2013 at 12:30 p.m. EDT at the Eighth Annual JMP Securities Healthcare
Conference in New York City.

A live and archived webcast of the presentation will be accessible on the
Biodel website at www.biodel.com under "Webcasts" in the "News & Events"
section.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for diabetes that
may be safer, more effective and more convenient for patients. We develop our
product candidates by applying our proprietary formulation technologies to
existing drugs in order to improve their therapeutic profiles. More
information about Biodel is available at www.biodel.com.

BIOD-G

CONTACT: Seth D. Lewis, +1-646-378-2952